Brian Druker, MD, Professor and Director of the OHSU Knight Cancer Institute, was recently featured in the online edition of Forbes magazine. The article focused on drug technology as it relates to leukemia and cancer, asking the question: Why aren’t there more cancer cures? Dr. Druker, whose research led to the development of Gleevec, was optimistic about the future of tumor-fighting drugs. Dr. Druker said, “Who would have thought a decade ago that you could give a pill to a melanoma or lung cancer patient and have their tumor melt away, even if it is only for six months?”
Read article at forbes.com
August 13, 2010
Portland, Ore.